MAPT and Alzheimer disease: Specifically, phosphorylated tau on threonine-181 (pTau181) and on threonine-217 (pTau217) have recently emerged as promising plasma biomarkers for AD, reflecting Aβ deposition as well as subsequent tau aggregation in the brain [5–7].